Advertisement

Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study

  • Takuya OyakawaEmail author
  • Nao Muraoka
  • Kei Iida
  • Masatoshi Kusuhara
  • Keita Mori
Original Article

Abstract

Background

The efficacy of direct oral anti-coagulants (DOACs) for the treatment of venous thromboembolism (VTE) in Japanese patients with advanced cancer is largely unknown.

Methods

This prospective single-center observational study enrolled Japanese patients with unresectable advanced cancer who started DOAC treatment for new-onset VTE between December 2015 and May 2018. Patients were followed for 3 months to evaluate bleeding and VTE recurrences. The primary study endpoint was major and non-major bleeding.

Results

One hundred and forty-five of 147 enrolled patients were analyzed. Of these, 8 [5.5%, 95% confidence interval (CI) 2.8–10.5] and 29 patients (20%, 95% CI 14.3–27.2) experienced major and non-major bleeding, respectively. Patients with bleeding were more likely to have a poor performance status (PS) [hazard rate (HR) 2.04, 95% CI 1.15–3.63] and more frequent use of non-steroidal anti-inflammatory drugs (NSAIDs) (HR 2.75, 95% CI 1.62–4.67) relative to those without bleeding. In a multivariate analysis, combined DOAC and NSAID use correlated significantly with bleeding (odds ratio 4.63, 95% CI 1.70–12.9, p = 0.003). Among 105 of 145 patients included in the VTE recurrence assessment, 9 experienced a VTE recurrence (8.6%, 95% CI 4.6–15.5).

Conclusions

Our findings confirm the risk of bleeding during DOAC treatment for VTE in Japanese patients with advanced cancer, particularly those with poor PS and those using NSAIDs. The risk of bleeding in these patients may be reduced by avoiding the combined use of DOACs and NSAIDs.

Keywords

Advanced cancer Venous thromboembolism Pulmonary thromboembolism Direct oral anti-coagulant Bleeding Cardio-oncology 

Notes

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815CrossRefGoogle Scholar
  2. 2.
    Cronin-Fenton DP, Søndergaard F, Pedersen LA et al (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer 103:947–953CrossRefGoogle Scholar
  3. 3.
    Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464CrossRefGoogle Scholar
  4. 4.
    Hutten BA, Prins MH, Gent M et al (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078–3083CrossRefGoogle Scholar
  5. 5.
    Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488CrossRefGoogle Scholar
  6. 6.
    Büller HR, Décousus H, Grosso MA et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415CrossRefGoogle Scholar
  7. 7.
    Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153CrossRefGoogle Scholar
  8. 8.
    Akl EA, Labedi N, Barba M et al (2011) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 6:CD006650Google Scholar
  9. 9.
    Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefGoogle Scholar
  10. 10.
    Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 12:2187–2191CrossRefGoogle Scholar
  11. 11.
    Raskob GE, van Es N, Segers A et al (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol:e379–e387Google Scholar
  12. 12.
    Levine MN, Gu C, Liebman HA et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10:807–814CrossRefGoogle Scholar
  13. 13.
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefGoogle Scholar
  14. 14.
    Buller HR, Cohen AT, Cohen AT et al (2007) Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357:1094–1104CrossRefGoogle Scholar
  15. 15.
    Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615–624CrossRefGoogle Scholar
  16. 16.
    Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor With low molecular weight heparin in patients With cancer With venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36:2017–2023CrossRefGoogle Scholar
  17. 17.
    Noble SI, Shelley MD, Coles B et al (2008) Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9:577–584CrossRefGoogle Scholar
  18. 18.
    Lamberts M, Lip GY, Hansen ML et al (2014) Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 161:690–698CrossRefGoogle Scholar
  19. 19.
    Davidson BL, Verheijen S, Lensing AW et al (2014) Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174:947–953CrossRefGoogle Scholar
  20. 20.
    Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352CrossRefGoogle Scholar
  21. 21.
    Konstantinides SV, Torbicki A, Agnelli G et al (2014) ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3080CrossRefGoogle Scholar
  22. 22.
    Zabrocka E, Wojtukiewicz MZ, Sierko E (2018) Thromboprophylaxis in cancer patients in hospice. Adv Clin Exp Med 27:283–289CrossRefGoogle Scholar
  23. 23.
    Oyakawa T, Muraoka N, Iida K et al (2017) Direct oral anticoagulant for the treatment of venous thromboembolism in Japanese patients with cancer. Palliat Care Res 12:175–182CrossRefGoogle Scholar
  24. 24.
    Khorana AA, Dalal M, Lin J et al (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648–655CrossRefGoogle Scholar
  25. 25.
    Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Takuya Oyakawa
    • 1
    Email author
  • Nao Muraoka
    • 1
  • Kei Iida
    • 1
  • Masatoshi Kusuhara
    • 2
  • Keita Mori
    • 3
  1. 1.Division of CardiologyShizuoka Cancer CenterShizuokaJapan
  2. 2.Research InstituteShizuoka Cancer CenterShizuokaJapan
  3. 3.Clinical Research Promotion Unit, Clinical Research Support CenterShizuoka Cancer CenterShizuokaJapan

Personalised recommendations